Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.

ABSTRACT: The management of type 2 diabetes not only requires effective medications to regulate blood glucose levels, but also needs to consider the economic implications. Liraglutide, dulaglutide, and semaglutide, three widely-used glucagon-like peptide-1 receptor agonists, have shown significant efficacy in diabetes treatment. This review aimed to systematically assess the cost-effectiveness of liraglutide in comparison to dulaglutide or oral semaglutide for treating type 2 diabetes. A comprehensive literature search was performed in PubMed, Web of Science, Scopus, Embase, and Cochrane. Studies published up to December 31, 2024 were retrieved. Two independent reviewers carefully screened the titles, abstracts, and full-text articles, and any disagreements were resolved with the involvement of a th

SUBMITTER: Wang L 

PROVIDER: S-EPMC12382109 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature